While these inhibitors have been shown to elicit tumor regression in MMTV-v-HRAS mice, they have yet to induce significant tumor regression in KRAS driven tumors and have not been tested in bAVMs [227–230]. The gene discussed is KRAS; the disease is neoplasm.